⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ADIL News
Adial Pharmaceuticals, Inc
Alcoholism Treatment Market Report 2026: Revenue to Reach $36.85 Billion in 2026, Growing by $2.27 Billion YoY
globenewswire.com
ADIL
ALKS
AZN
BCO
CATX
LLY
GSK
MRK
PFE
SNY
TEVA
Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045
globenewswire.com
ADIL
Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program
globenewswire.com
ADIL
Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial
globenewswire.com
ADIL
Form 8-K
sec.gov
ADIL
Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans
globenewswire.com
ADIL
Form 8-K
sec.gov
ADIL
Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update
globenewswire.com
ADIL
Form 8-K
sec.gov
ADIL
Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement
globenewswire.com
ADIL